Although the meeting vote wasnt positive, I think there is still an upside to this stock.

MIAMI, FL, May 09, 2007 (MARKET WIRE via COMTEX) -- DOR BioPharma, Inc. ("DOR," or "The Company") announced today that the Oncologic Drugs Advisory Committee ("ODAC") appointed by the U.S. Food and Drug Administration ("FDA") voted that the data supporting orBec(R) (oral beclomethasone dipropionate) did not show substantial evidence of efficacy by a margin of 7 to 2 for the treatment of gastrointestinal graft-versus-host disease ("GI GVHD"). The FDA is not bound by ODAC's recommendations, but it will take the panel's advice into consideration when reviewing the New Drug Application ("NDA") for orBec(R). The FDA has said it will respond to DOR's NDA by July 21, 2007, under Prescription Drug User Fee Act ("PDUFA") guidelines.